Progenics Pharmaceuticals, Inc. (PGNX) Misses Q2 EPS by 3c

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) reported Q2 EPS of ($0.17), $0.03 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.83 million.

For earnings history and earnings-related data on Progenics Pharmaceuticals, Inc. (PGNX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c